Clinical

Articles

Developed by Regeneron Pharmaceuticals and Sanofi, Dupixent reduced severe asthma attacks and improved lung function in children 6 to 11 years.



FDA Approves Dupixent for Children with Asthma

The agency cited an open inspection issue at a facility that performs analytical testing of drug substance.

FDA Issues Complete Response Letter for Tyvaso DPI

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

The agency also granted tezepelumab priority review with a PDUFA date sometime in the first quarter of 2022.

Amgen Submits Application for Asthma Biologic

The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.

Self-injectable respiratory medication opens doors for patients with severe asthma

Budesonide/Formoterol maintenance and reliever therapy is an effective option for patients requiring treatment adjustments across Steps 2 to 4 of the Global Initiative for Asthma guidelines, according to the results of a study published online, June 2 in Respiratory Research.

BUD/FORM maintenance and reliever therapy effective asthma control

Use of short- and long-acting inhaled anticholinergic medications in men with chronic obstructive pulmonary disease is associated with an increased risk of acute urinary retention, according to the results of a study published in the May 23 issue of Archives of Internal Medicine.

IACs linked to increased risk of acute urinary retention in men with COPD

Pirfenidone, an investigational drug (InterMune) that inhibits the synthesis of TGF-beta and TNF-alpha, was associated with positive effects on lung function, 6-minute walk test distance, and progression-free survival in patients with mild-to-moderate idiopathic pulmonary fibrosis, according to a study published in The Lancet.

Study: Pirfenidone shows promise 
as IPF treatment option

For the fourth consecutive year, diabetes therapy topped the list of contributors to drug use trends in therapeutic categories, contributing 16.1% to overall growth in drug spending in 2010 due to an increasing number of patients, according to the recently released 2011 Medco Drug Trend Report, which tracks utilization and spending.

Breaking News: Diabetes, specialty drugs continue to drive growth in drug spending

New molecular entity: Roflumilast oral treatment was approved by FDA as treatment to reduce risk of COPD exacerbations.

Roflumilast oral treatment (Daliresp): Treatment to reduce COPD exacerbations in patients with severe COPD associated with chronic bronchitis

The anticholinergic drug tiotropium is more effective than the ?2-agonist salmeterol in preventing exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease, according to a multicenter European study published in the New England Journal of Medicine.